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Abstract Matrix metalloproteinase (MMP)-19 and MMP-20
(enamelysin) are two recently discovered members of the MMP
family. These enzymes are involved in the degradation of the
various components of the extracellular matrix (ECM) during
development, haemostasis and pathological conditions. Whereas
MMP-19 mRNA is found widely expressed in body tissues,
including the synovium of normal and rheumatoid arthritic
patients, MMP-20 expression is restricted to the enamel organ.
In this study we investigated the ability of MMP-19 and MMP-
20 to cleave two of the macromolecules characterising the
cartilage ECM, namely aggrecan and the cartilage oligomeric
matrix protein (COMP). Both MMPs hydrolysed aggrecan
efficiently at the well-described MMP cleavage site between
residues Asn341 and Phe342, as shown by Western blotting using
neo-epitope antibodies. Furthermore, the two enzymes cleaved
COMP in a distinctive manner, generating a major proteolytic
product of 60 kDa. Our results suggest that MMP-19 may
participate in the degradation of aggrecan and COMP in
arthritic disease, whereas MMP-20, due to its unique expression
pattern, may primarily be involved in the turnover of these
molecules during tooth development. ß 2000 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Matrix metalloproteinases (MMPs) are a group of homol-
ogous zinc-dependent endopeptidases that can degrade all ma-
jor components of the extracellular matrix (ECM). This class
of enzymes has been implicated in connective tissue remodel-
ling during normal and pathological conditions [1,2]. Elevated
levels of some MMPs have been detected in the cartilage and
synovial £uid of arthritis patients, indicating a role for these
enzymes during cartilage destruction in this type of degener-
ative disease and in vitro models support this role by showing
increased MMP-mediated hydrolysis of cartilage macromole-
cules upon treatment with cytokines or retinoic acid [3^6].
MMP-19 and MMP-20 are newly identi¢ed members of the
MMP family [7^9]. Despite their classical MMP domain
structure, including a signal sequence, a latency domain, a
catalytic domain and a COOH-terminal domain with se-
quence similarity to haemopexin, these enzymes lack a series
of structural features distinctive of the diverse MMP subfam-
ilies. Therefore, it was proposed that MMP-19 and MMP-20
belong to new MMP subfamilies. MMP-19 might play a role
in arthritis since serum anti-MMP-19 autoantibody titres seem
to be frequent among rheumatoid arthritis (RA) patients [10].
Furthermore, MMP-19 mRNA has been found constitutively
expressed in RA and traumatic synovial membranes [11].
MMP-20 was cloned from odontoblastic cells, which are in-
volved in matrix remodelling during enamel maturation, and
the enzyme was shown to cleave the major component of teeth
ECM, amelogenin [9].
Degradation of aggrecan, the major proteoglycan of the
cartilage ECM responsible for the load-bearing and elastic
properties of this tissue, is one of the earliest detectable events
in arthritic cartilage degeneration. MMPs have been impli-
cated in proteolysis and the subsequent loss of aggrecan
from cartilage during arthritis [12^15]. The loss of this hya-
luronan-bound macromolecule from cartilage tissue is due to
proteolytic cleavage within the inter-globular domain (IGD)
of its core protein, thereby releasing a major fragment con-
taining most of the glycosaminoglycan chains into the joint
£uid (Fig. 1). The major MMP cleavage site within the IGD is
between residues N341 and F342. Stromelysins, collagenases,
gelatinases, MT1-MMP and matrilysin cleave at this site, gen-
erating new NH2- or COOH-terminal sequences that are rec-
ognised by speci¢c neo-epitope antibodies [12,16^19]. Neo-
epitope antibodies have been used to detect aggrecan frag-
ments in cartilage and synovial £uid from RA patients, pro-
viding evidence for cleavage at this site in vivo and implicating
MMPs in aggrecan turnover during arthritic disease
[12,14,15,20,21]. Analysis of the aggrecan degradation prod-
ucts found in the joint space during arthritis indicated, how-
ever, that another distinct class of enzymes, hydrolysing the
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 8 1 9 - 6
*Corresponding author. Fax: (44)-1603-592250.
E-mail: j.stracke@uea.ac.uk
Abbreviations: MMP, matrix metalloproteinase; IGD, inter-globular
domain; COMP, cartilage oligomeric matrix protein; ECM, extracel-
lular matrix; RA, rheumatoid arthritis; OA, osteoarthritis
FEBS 23938 21-7-00
FEBS 23938FEBS Letters 478 (2000) 52^56
Glu373^Ala bond within the IGD, contributes towards the loss
of cartilage aggrecan (Fig. 1). The enzymes responsible for
this proteolysis were recently identi¢ed as members of the
ADAMTS group of metalloproteinases [22,23]. Large hyalur-
onan-binding proteoglycans, like aggrecan, are also major
components of the early tooth ECM and proteolytic process-
ing by MMPs may play a part in the turnover of this speci¢c
ECM during development [24,25].
Another important component of the ECM of joint tissues,
is cartilage oligomeric matrix protein (COMP), a pentameric
protein predominantly expressed in cartilage and tendon
[26,27]. This molecule plays an important role in the accumu-
lation and integrity of the cartilage ECM. Fragments of
COMP were found in serum and synovial £uid from RA
and osteoarthritis (OA) patients [28^32], and MMPs have
been implicated in the cleavage of COMP during the arthri-
tides, since hydroxamic acid-based MMP inhibitor BB-94 in-
hibited degradation in a cartilage explant model [33,34].
To investigate the possible roles of MMP-19 and -20 in the
progression of RA and the turnover of tooth ECM, respec-
tively, we examined the catalytic domains of these two en-
zymes in terms of their ability to cleave aggrecan and
COMP in vitro using sodium dodecyl sulfate^polyacrylamide
gel electrophoresis (SDS^PAGE) and Western blot analysis.
2. Materials and methods
A chemiluminescence blotting substrate kit was purchased from
Pierce, USA. Nitrocellulose membrane was from Amersham, USA.
Agarose type HSC was from PS Park Scienti¢c (Northampton,
UK). Native pig aggrecan G1-G2 and recombinant human G1-G2
fragments have been obtained as described previously [35,36]. Bovine
aggrecan (A1D1) was a generous gift from Professor Michael Bayliss
and Dr. Jay Dudhia, Royal Veterinary College, London, UK. COMP
was puri¢ed from human articular cartilage as previously described
[27]. All other reagents were of analytical grade.
2.1. Expression, refolding and puri¢cation of the catalytic domains of
MMP-19 and MMP-20
COOH-terminal deletion mutants of MMP-19 (prov260ÿ508MMP-
19) (GenBank/EBI accession number x92521) and MMP-20 (EMBL
accession number y12779) were expressed in Escherichia coli, refolded
and puri¢ed as described previously [7,9].
2.2. MMP cleavage of G1-G2 aggrecan, aggrecan and COMP
Digestion of native pig aggrecan G1-G2, recombinant human G1-
G2 aggrecan and bovine aggrecan was performed at 37‡C in bu¡er
containing 50 mM Tris^HCl pH 7.6, 150 mM NaCl, 10 mM CaCl2,
0.05% (v/v) Brij 35. Apart from recombinant human G1-G2, which
was digested for 3.5 h, incubation was performed overnight. Bovine
aggrecan (A1D1) was used at 100 Wg/ml, human and pig G1-G2
aggrecan were used at 250 Wg/ml in the cleavage assay. MMP-19
catalytic domain (4 WM) and MMP-20 catalytic domain (30 WM)
were used at various concentrations (4 nM, 12 nM, 24 nM, 40 nM
and 120 nM) in the assay. Cleavage was stopped by addition of
EDTA and 1,10-phenanthroline to ¢nal concentrations of 10 mM
and 2 mM, respectively. COMP was incubated in a time-course ex-
periment at 37‡C with MMP-19 and MMP-20 catalytic domain, re-
spectively, in the above bu¡er using an enzyme/substrate ratio (w/w)
of 1/20 prior to analysis by SDS^PAGE and Western blotting.
2.3. Western blot analysis of aggrecan cleavage
Samples were electrophoresed on 5% SDS gels or agarose^acrylam-
ide composite gels [37] prior to electroblotting onto nitrocellulose
membrane and analysed for AF-28 epitope (1:1000), ...DIPEN epi-
tope (1:1000) and ...ITEGE epitope (1:1000). Characterisation of
monoclonal antibody AF-28 [38], and polyclonal anti-ITEGE and
anti-DIPEN antisera [36] have been described. Rabbit anti-mouse
and goat anti-rabbit horseradish peroxidase conjugated immunoglob-
ulin were purchased from Dako (Denmark). The monoclonal anti-
body AF-28 detects the NH2-terminal sequence FFGVG... of G2
fragments derived from MMP cleavage. Polyclonal anti-ITEGE anti-
body recognises the COOH-terminal epitope ...ITEGE of G1 frag-
ments produced by aggrecanase cleavage. Polyclonal anti-DIPEN
antibody recognises the COOH-terminal epitope ...DIPEN of G1
fragments produced by MMP cleavage.
3. Results
3.1. Digestion of native and recombinant G1-G2 aggrecan and
whole aggrecan with the catalytic domains of MMP-19
and MMP-20
To determine the ability of MMP-19 and MMP-20 to
cleave aggrecan at the major ...DIPEN341^FFGVG... site
identi¢ed for cleavage by other MMPs, two aggrecan G1-
G2 fragments, one isolated from pig laryngeal cartilage [35]
and the other expressed in a baculovirus expression system
[36], were incubated with various amounts of these enzymes.
The cleavage products were analysed by Western blotting to
identify the generated fragments. Both MMP-19 and MMP-20
were able to digest native (data not shown) and recombinant
G1-G2 e⁄ciently (Figs. 2 and 3). Cleavage of both G1-G2
substrates by MMP-19 resulted in the appearance of a prod-
uct of 55 kDa on silver-stained SDS gels at enzyme/substrate
ratios of approximately 1/500 (data not shown). The size of
the fragment coincides with the predicted mass of the MMP-
generated G1 fragment. This was con¢rmed by Western blot
analysis using the anti-DIPEN antibody (Figs. 2A and 3A,
not shown for pig G1-G2). Digest of the recombinant G1-
G2 substrate resulted in a product containing G2 of about
60 kDa, which was detected by the AF-28 antibody (Figs.
2B and 3B). In addition, cleavage of native pig G1-G2 by
MMP-19 generates a product of about 120 kDa, correspond-
ing with the size of the G2 fragment, as shown by SDS^
PAGE and Western blot using the same antibody (data not
shown). Western blot analysis using the anti-ITEGE anti-
body, recognising the aggrecanase cleavage site, revealed
that neither MMP-19 nor MMP-20 were able to cleave at
this site (data not shown). Here we showed that MMP-19
generates the same cleavage products from both substrates
as MMP-20, as shown by Western blot analysis.
After employing the truncated aggrecan substrates, we in-
vestigated whether MMP-19 and MMP-20 also cleave native
aggrecan within the IGD. Therefore, whole bovine aggrecan
(A1D1) was incubated with the catalytic domains of MMP-19
Fig. 1. Schematic representation of the cleavage sites in the aggre-
can IGD. G1, G2 and G3 represent the globular domains of the ag-
grecan protein core and IGD is the inter-globular domain between
G1 and G2. The main MMP and aggrecanase cleavage sites in the
IGD are indicated with arrows.
FEBS 23938 21-7-00
J.O. Stracke et al./FEBS Letters 478 (2000) 52^56 53
and MMP-20 in a time-dependent fashion and analysed for
the COOH-terminal G1 neo-epitope ...DIPEN (Fig. 4). The
digestions generated G1 fragments that were immunodetected
with the anti-DIPEN antibody. The fragment displayed a
mass of approximately 60 kDa which corresponds to the G1
fragment of MMP-cleaved aggrecan.
These results show that MMP-19 and MMP-20 display the
same speci¢city for the aggrecan IGD as other members of the
MMP family [16,39]. Neither MMP-19 nor MMP-20 catalytic
domain were able to cleave aggrecan at the aggrecanase site
(E373^A374) since no signal was obtained by Western blotting
with anti-ITEGE antibody, which recognises aggrecanase-gen-
erated G1 neo-epitopes (data not shown).
3.2. Digestion of COMP with the catalytic domains of
MMP-19 and MMP-20
The COMP, a pentameric protein involved in the crosslink-
ing of cartilage components, was digested in a time-dependent
manner with the catalytic domains of MMP-19 and MMP-20,
using an enzyme/substrate ratio (w/w) of 1/20 (Fig. 5). Similar
cleavage patterns were obtained with both enzymes. The 100
kDa monomer was degraded by both enzymes almost com-
pletely after 20 h of incubation to one major fragment of
60 kDa.
Fig. 2. Western blot analysis of the digestion of recombinant G1-
G2 aggrecan (250 Wg/ml) with the catalytic domain of MMP-19.
Cleavage was performed for 3.5 h at 37‡C with various concentra-
tions of enzyme. A: Western blot analysis using Anti-DIPEN neo-
epitope antibody. B: Western blot analysis using anti-FFGVG...
neo-epitope antibody AF-28. The enzyme concentrations used,
were: lanes 1: no enzyme, lanes 2: 4 nM, lanes 3: 12 nM, lanes 4:
24 nM, lanes 5: 40 nM, lanes 6: 120 nM.
Fig. 3. Western blot analysis of the digestion of recombinant G1-
G2 aggrecan (250 Wg/ml) with the catalytic domain of MMP-20.
Cleavage was performed for 3.5 h at 37‡C with various concentra-
tions of enzyme. A: Western blot analysis using Anti-DIPEN neo-
epitope antibody. B: Western blot analysis using anti-FFGVG...
neo-epitope antibody AF-28. The enzyme concentrations used,
were: lanes 1: no enzyme, lanes 2: 4 nM, lanes 3: 12 nM, lanes 4:
24 nM, lanes 5: 40 nM, lanes 6: 120 nM.
Fig. 4. Western blot analysis of the digestion of aggrecan (A1D1,
100 Wg/ml) puri¢ed from bovine nasal cartilage with the catalytic
domains of MMP-19 and MMP-20. Cleavage was performed over-
night at 37‡C with various concentrations of enzyme. Anti-DIPEN
neo-epitope antibody was used for the detection of cleavage prod-
ucts. A: Digestion with MMP-19 catalytic domain. B: Digestion
with MMP-20 catalytic domain. The enzyme concentrations used,
were: lanes 1: no enzyme, lanes 2: 4 nM, lanes 3: 12 nM, lanes 4:
24 nM, lanes 5: 40 nM, lanes 6: 120 nM.
Fig. 5. SDS^PAGE (6%) analysis: COMP cleavage by the catalytic
domains of MMP-19 and MMP-20 at 37‡C. The enzyme/substrate
ratio used in this experiment was 1/20 (w/w). Lane O: original pro-
tein, lane C: control, lanes 1: 1 h incubation, lanes 2: 5 h incuba-
tion, lanes 3: overnight incubation.
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4. Discussion
In recent years MMPs have been implicated in the degra-
dation of aggrecan since elevated levels of several MMPs are
found in cartilage, synovial £uids and serum from arthritis
patients. Furthermore, synthetic MMP inhibitors were shown
to prevent aggrecan loss from cartilage. Neo-epitope antibod-
ies recognising aggrecan fragments generated by the action of
MMPs, were used to con¢rm the presence of speci¢c MMP
degradation products in vivo [14,15,20,21]. Furthermore, all
MMPs tested exhibit the same speci¢city for the Asn341^Phe
bond located within the IGD of aggrecan (Fig. 1). Although
the recently discovered aggrecanases 1 and 2, both members
of the ADAMTS family [22,23], are thought to be the major
players in aggrecan loss from cartilage, it is evident that
MMPs have a distinct role in cartilage proteoglycan turnover
[14,15,21,39]. The quanti¢cation of aggrecanase and MMP
involvement in aggrecan loss has not been done and further
studies are needed to determine which of these enzyme fami-
lies plays the major role during pathological conditions and
normal aggrecan metabolism. MMP-19 is a recently described
member of the MMP family [8] and the mRNA was found
associated with proliferating chondrocytes in the chondro-
epiphysis of mouse embryos during musculoskeletal develop-
ment (Suneel Apte, personal communication). Since prolifer-
ating chondrocytes are a hallmark of cartilage destruction
during arthritis, MMP-19 has been suggested to play a dis-
tinctive role in this process. Interestingly, MMP-19 mRNA is
constitutively expressed in arthritic and traumatic synovial
membranes [11], a tissue which expresses high levels of stro-
melysin-1 (MMP-3). In contrast to stromelysin-1, which is
found in high concentrations as a latent zymogen in synovial
£uid from arthritis patients [40], MMP-19 is able to autoacti-
vate and could therefore exhibit a considerable impact on
cartilage aggrecan [7].
MMP-20 is also a newly discovered MMP, cloned from
odontoblastic cells and implicated in the matrix turnover dur-
ing teeth development [9,41,42]. Since MMP-20 mRNA ex-
pression was only found in the enamel organ and not in
RA cartilage or synovium, the enzyme may be involved dur-
ing aggrecan turnover in the developing teeth [11,41,42].
In this study, the ability of both enzymes to cleave the large
ECM proteoglycan aggrecan was investigated. MMP-19 and
MMP-20 were both able to cleave native bovine aggrecan, pig
G1-G2 and human recombinant G1-G2 within the IGD. Both
enzymes demonstrate speci¢city for the MMP cleavage site
Asn341^Phe whereas they were not able to hydrolyse aggrecan
at the aggrecanase site Glu373^Ala as shown by immunode-
tection of the generated neo-epitopes. The two enzymes there-
fore conform with the speci¢city pro¢le of all other MMPs
tested so far, for cleavage at the Asn341^Phe bond. The pos-
sibility that these two enzymes hydrolyse aggrecan at other
sites, as shown for other MMPs [16,39], remains to be inves-
tigated and could lead to new clues about the function of
MMP-19 and MMP-20 during aggrecan metabolism in tissues
where they are prominently expressed.
We could also show in this study that both, MMP-19 and
MMP-20 were able to cleave the cartilage macromolecule
COMP in a distinct manner. Although both MMPs generate
one major cleavage product of about 60 kDa, MMP-19 seems
to be slightly more e⁄cient in cleaving COMP than MMP-20.
COMP fragments in serum and synovial £uid from OA and
RA patients have earlier been identi¢ed as markers for these
diseases [28^32]. It has been suggested that MMPs play a role
in the hydrolysis of COMP and, therefore, compromise the
integrity of the cartilage ECM structure leading to the ulti-
mate loss of joint function [33,34].
However, the role of these two enzymes in vivo against
aggrecan and COMP substrates is not known and further
work is required to establish the function of the here-de-
scribed MMPs in human disease.
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